Shares if VivoSim Labs, Inc. (VIVS) are down about 34% in pre-market trading after the company announced the pricing of up to a $4 million best-efforts public offering, structured across two closings.
VivoSim said the offering includes $3 million funded at an initial closing and another $1 million to be funded 30th day following the date of the initial closing, subject to certain conditions. The initial closing is expected to occur on April 1, 2026, pending customary conditions.
At the initial closing, the company will issue and sell $3 million in common stock or pre-funded warrants at a subscription price of $1.140 per share and $1.139 per pre-funded warrant, representing 286,557 common shares and 2,345,022 pre-funded warrants. VivoSim will also issue 3,947,369 common warrants to purchase up to 150% of the aggregate number of shares sold.
The common warrants will have an exercise price of $1.710, be immediately exercisable, and expire five years from issuance. The pre-funded warrants will have an exercise price of $0.001, be immediately exercisable, and expire when fully exercised.
The second closing will involve the sale of an additional $1 million in common stock and a new set of common warrants equal to 150% of the securities sold in that tranche. Completion of the second tranche is subject to conditions including minimum closing price and average trading volume requirements.
Joseph Gunnar & Co., LLC is acting as the exclusive placement agent for the offering.
The company implemented a 1-for-12 reverse stock split on March 17, 2025.
VIVS closed Tuesday's trading at $1.43, up 3.62%. In the pre-market the stock is trading at $0.93, down 34.19%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.